About Us

GlycoMira's technology was the result of a casual challenge from practicing pulmonary physician Tom Kennedy (right) to medicinal chemist Glenn Prestwich (second) to try to make a non-porcine derived replacement for non-anticoagulant heparin derivatives. The data from the first compounds - called SAGEs, or semi-synthetic glycosaminoglycan ethers - were so encouraging, that GlycoMira was launched in Apr 2008 with funding from a Utah State Centers of Excellence licensee grant. Glenn Prestwich recruited his pilot friend and business partner, W. Tim Miller (third, President and CEO of the combined Echelon Biosciences-Frontier Scientific companies) to serve as Acting President during the company formation. Together, Tim Miller and Glenn Prestwich recruited G. Thomas Heath (left), the first president of Echelon Biosciences, as Chair of the Board of Directors to complete the team. With initial private investments, SBIRs and university funds, GlycoMira has demonstrated safety and efficacy of a number of its SAGEs against a broad spectrum of RAGE-mediated inflammatory diseases. GlycoMira's strong team with its novel technology and excellent traction is committed to expediting the delivery of new therapeutics to the clinic.

Terms  |  Report Abuse  |  Print page  |  Powered by Google Sites